Real-life management of drug–drug interactions between antiretrovirals and statins

Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association

(2019) Matthew J. Feinstein et al.   CIRCULATION

Effect of DS-8500a, a Novel G Protein-Coupled Receptor 119 Agonist, on the Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects

(2019) Yutaro Maekawa et al.   CLINICAL DRUG INVESTIGATION

Non-AIDS comorbidity burden differs by sex, race, and insurance type in aging adults in HIV care

(2019) Frank J. Palella et al.   AIDS

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV

(2019) Perrine Courlet et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications

(2018) Felix Stader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Real-life achievement of lipid-lowering treatment targets in the DIAbetes and LifEstyle Cohort Twente: systemic assessment of pharmacological and nutritional factors

(2018) Christina M. Gant et al.   Nutrition & Diabetes

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

(2018) Lucia Taramasso et al.   BMC INFECTIOUS DISEASES

Evaluation of the concentrations of psychotropic drugs in HIV-infected versus HIV-negative patients: Potential implications for clinical practice

(2018) Dario Cattaneo et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

HIV-infected patients' beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy

(2017) S Kamal et al.   HIV MEDICINE

Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study

(2016) Giuseppe Vittorio De Socio et al.   INFECTION

Statins for Prevention of Cardiovascular Disease in Adults

(2016) Roger Chou et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Low-Density Lipoprotein Cholesterol Levels and Statin Treatment by HIV Status Among Multicenter AIDS Cohort Study Men

(2015) Anne K. Monroe et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Pharmacokinetic Drug–Drug Interaction Study Between Raltegravir and Atorvastatin 20 mg in Healthy Volunteers

(2015) Maren Blonk et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

(2013) E. G. J. Hulskotte et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study

(2013) Line D. Rasmussen et al.   PLoS One

HIV Infection and the Risk of Acute Myocardial Infarction

(2013) Matthew S. Freiberg et al.   JAMA Internal Medicine

Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy

(2012) J Myers et al.   HIV MEDICINE

Statin-Associated Rhabdomyolysis: Is There a Dose-Response Relationship?

(2011) Anne Holbrook et al.   CANADIAN JOURNAL OF CARDIOLOGY

Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers

(2011) Jonathan Bullman et al.   EPILEPSIA

Steady-State Pharmacokinetic Interactions of Darunavir/Ritonavir With Lipid-Lowering Agent Rosuvastatin

(2011) Divya Samineni et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Influence of Drug Transport Proteins on the Pharmacokinetics and Drug Interactions of Hiv Protease Inhibitors

(2011) Latoya Griffin et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada

(2011) Anselm K Gitt et al.   European Journal of Preventive Cardiology

Impact of OATP transporters on pharmacokinetics

(2009) A Kalliokoski et al.   BRITISH JOURNAL OF PHARMACOLOGY

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics and tolerability of multiple-dose rosuvastatin: An open-label, randomized-sequence, three-way crossover trial in healthy Chinese volunteers

(2009) Ruoqi Zhang et al.   CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL

Effects of Atazanavir/Ritonavir or Fosamprenavir/Ritonavir on the Pharmacokinetics of Rosuvastatin

(2009) Anthony J Busti et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Quantitative Population Pharmacokinetic Analysis of Pravastatin Using an Enterohepatic Circulation Model Combined With Pharmacogenomic Information onSLCO1B1andABCC2Polymorphisms

(2009) Takafumi Ide et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy

(2009) S P R Romaine et al.   PHARMACOGENOMICS JOURNAL

Rosuvastatin, Pravastatin, and Atorvastatin for the Treatment of Hypercholesterolaemia in HIV-Infected Patients Receiving Protease Inhibitors

(2008) Leonardo Calza et al.   CURRENT HIV RESEARCH

Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers

(2008) Jennifer J Kiser et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES